[Results of the treatment of gastroesophageal reflux and peptic esophagitis using cisapride].
Cisapride is a new prokinetic agent that acts at gastric emptying, esophagic peristalsis and the pressure of the low esophagic sphincter. In the present study we grave Cisapride for 12 weeks to 34 patients with severe pathologic gastroesophageal reflux and/or peptic esophagitis. The results show an important improvement of the clinic, pH monitoring, endoscopic and histologic alterations.
Carrasco Gandía
S
S
Unidad de Gastroenterología y Nutrición, Hospital Infantil de la Seguridad Social La Paz, Madrid.
Lama Moré
R
R
Prieto Bozano
G
G
Polanco Allue
I
I
D020117:Cisapride; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects; D005750:Gastric Juice / Q000737:chemistry; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D010528:Peristalsis / Q000187:drug effects; D010880:Piperidines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D010880:Piperidines; D012702:Serotonin Antagonists; D020117:Cisapride
Resultados del tratamiento del reflujo gastroesofágico y la esofagitis péptica con Cisapride.